Predicting durable remissions following thalidomide therapy for relapsed myeloma

References

• Durie B G, Bataille R. Therapeutic implications of myeloma staging. Eur J Haematol Suppl 1989; 51: 111–116
   PubMedGoogle Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Durie B G, Harousseau J L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 2220
   Web of Science ®Google Scholar
• Anderson J R, Cain K C, Gelber R D. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710–719
   PubMed Web of Science ®Google Scholar
• Baldini L, Radaelli F, Chiorboli O, Fumagalli S, Cro L, Segala M, et al. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer 1991; 68: 62–67
   PubMed Web of Science ®Google Scholar
• Palmer M, Belch A, Hanson J, Brox L. Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br J Cancer 1989; 59: 110–112
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Fonseca R, Dispenzieri A, Lacy M Q, Witzig T E, Lust J A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979–983
   PubMed Web of Science ®Google Scholar
• Tricot G, Reiner M, Sawyer J, Crowley J, Barlogie B. A complete remission (CR) is not a prerequisite for prolonged survival after autotransplants for multiple myeloma [abstract]. Blood 2004; 104: 926
   Google Scholar
• Kyle R A, Leong T, Li S, Oken M M, Kay N E, Van Ness B, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958–1966
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006; 107: 2633–2638
   PubMed Web of Science ®Google Scholar
• Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94–99
   PubMed Web of Science ®Google Scholar
• Marmont F, Levis A, Falda M, Resegotti L. Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. Ann Oncol 1991; 2: 191–195
   PubMed Web of Science ®Google Scholar
• Hussein M A, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81: 889–895
   PubMed Web of Science ®Google Scholar
• O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731–737
   PubMed Web of Science ®Google Scholar
• Alvares C L, Davies F E, Horton C, Patel G, Powles R, Sirohi B, et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005; 129: 607–614
   PubMed Web of Science ®Google Scholar
• Lahuerta J J, Martinez-Lopez J, Serna J D, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438–446
   PubMed Web of Science ®Google Scholar
• Davies F E, Forsyth P D, Rawstron A C, Owen R G, Pratt G, Evans P A, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112: 814–819
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Richardson P, Rajkumar S V, Sonneveld P, Schuster M, Coleman M, et al. Relationship Between Quality of Response to Bortezomib and Clinical Benefit in the APEX Trial [poster]. Eleventh International Myeloma Workshop. Greece, Kos Island 2007
   Google Scholar
• Mileshkin L, Biagi J J, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
   PubMed Web of Science ®Google Scholar
• Prince H M, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 5504–5514
   PubMed Web of Science ®Google Scholar
• Anderson J R, Cain K C, Gelber R D. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008; 26: 3913–3915
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560
   PubMed Web of Science ®Google Scholar
• Harousseau J, Weber D, Dimopoulos M, Olesnyckyj M, Yu Z, Zeldis J B, et al. Relapsed/refractroy multiple myeloma patients treated with lenalidoide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response [abstract]. Blood 2007; 110: 3598
   Google Scholar
• van Rhee F, Dhodapkar M, Shaughnessy J D, Jr, Anaissie E, Siegel D, Hoering A, et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008; 112: 1035–1038
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875–882
   PubMed Web of Science ®Google Scholar
• Quach H, Horvath N, Cannell P, Mikhael J, Butcher E, Prince H M. Efficacy results from an international expanded access program to bortezomib for patients wtih relapsed and/or refractory multiple myeloma: a subset analysis of the Australian & New Zealand data of 111 patients. Intern Med J 2008; 9999(999A)1–23
   Google Scholar